Litcius/Paper detail

Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003

Mark K. Buyyounouski, S. Pugh, R.C. Chen, M. Mann, Rajat J. Kudchadker, André Konski, Omar Y. Mian, Jeff M. Michalski, Éric Vigneault, Richard K. Valicenti, Maroie Barkati, C.A. Lawton, Louis Potters, Drew C. Monitto, J. Kittel, Thomas Michael Schroeder, Raquibul Hannan, Colin Duncan, Joseph P. Rodgers, Howard M. Sandler

2021International Journal of Radiation Oncology*Biology*Physics29 citationsDOIOpen Access PDF

Topics & Concepts

MedicineProstatectomyClinical endpointProstate cancerRadiation therapyUrologyAndrogen deprivation therapyProstateInternal medicineRandomized controlled trialOncologyCancerProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchHealth Systems, Economic Evaluations, Quality of Life
Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003 | Litcius